Lilly says retatrutide is ready to file, with US submission planned for early 2027

Eli Lilly says its investigational drug retatrutide has produced five positive phase 3 trials and is ready to be filed for approval. The company plans to seek US registration in three areas: obesity, obstructive sleep apnea and knee osteoarthritis pain, with a filing targeted for the first quarter of 2027 ^[1].

The most recent results come from TRIUMPH-3, a trial in people with severe obesity and established cardiovascular disease. In that trial, participants lost 22.6 percent of their body weight, according to the company ^[1]. TRIUMPH-2 has also been reported ^[1]. Lilly said the five positive phase 3 trials together give it the clinical package it needs to pursue registration in all three conditions ^[1].

Several details have not been reported. The number of participants in each trial, how long the trials ran, whether the 22.6 percent figure is an average for everyone enrolled or for a subgroup, and how retatrutide compared with a placebo have not been disclosed. Side effects, and how many people stopped treatment, have not been disclosed either. It also has not been reported whether each of the three conditions — obesity, obstructive sleep apnea and knee osteoarthritis pain — rests on its own dedicated trial or on shared data, or whether the company intends one filing or several.

Retatrutide is not approved and is not available by prescription. A decision to file is a step in the regulatory process, not a decision on approval.

Why it matters for patients

For anyone taking or considering a GLP-1 medication now, this changes nothing on its own. Retatrutide cannot be prescribed, and a filing in early 2027 would be followed by a review period whose length has not been reported. A possible approval would come months or longer after that, and no decision date has been given ^[1].

The 22.6 percent weight loss figure comes from one specific group: people with severe obesity and established cardiovascular disease ^[1]. Results in other groups of patients have not been reported, so it is not known whether similar results would appear elsewhere.

Lilly is asking regulators to review the drug for obstructive sleep apnea and knee osteoarthritis pain in addition to obesity ^[1]. If that happens, it would mean the drug is evaluated for health problems beyond weight loss, and potentially labeled for them. Whether the trials measured improvements in breathing during sleep, in knee pain, or in both, and how large those improvements were, has not been reported.

What happens next

Lilly has said it plans to file in the US in the first quarter of 2027 ^[1]. Whether that filing covers all three conditions at once, how long a review would take, when a decision might come, and what the drug would cost have not been disclosed ^[1].